Clarithromycin plus intravenous immunoglobulin therapy for Kawasaki disease, a phase 3, multicenter, randomized, double blind, placebo control study. - Clarithromycin plus intravenous immunoglobulin therapy for Kawasaki disease, a phase 3, multicenter, randomized, double blind, placebo control study.

Clinical Research Support Center Kyushu0 个研究点目标入组 250 人开始时间: 2016年10月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients with day 9 of illness or over, when day 1 defined as the first day of fever. 2.Those have received 14/15-membered ring macrolide. 3.Those with coronary artery abnormality at enrollment. 4.Relapse or recurrence of Kawasaki disease. 5.Those with suspicious origin of fever in addition to Kawasaki disease. 6.Those received intravenous immunoglobulin therapy within 90 days before enrollment. 7.Those with severe underlying disease. 8.Those who are receiving systemic immunosuppressant agent such as steroids at the enrollment. 9.Those with prolonged QT interval. 10.Those with a history of hypersensitivity reactions to macrolides. 11.Those who are receiving drugs which interact with clarithromycin 12.Any other patients who are regarded as unsuitable for this study by the investigators.

发起方

Clinical Research Support Center Kyushu